Európska únia - slovenčina - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vakcíny - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sasmar srl place du champs de mars 5/20 b-1050 brussels belgicko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sasmar srl place du champs de mars 5/20 b-1050 brussels belgicko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boiron, francúzsko - iné liečivá - 93 - homeopatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

faes farma, s.a., Španielsko - mesalazín - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

faes farma, s.a., Španielsko - mesalazín - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

faes farma, s.a., Španielsko - mesalazín - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

faes farma, s.a., Španielsko - mesalazín - 29 - antirheumatica, antiphlogistica, antiuratica

Európska únia - slovenčina - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vakcíny - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Európska únia - slovenčina - EMA (European Medicines Agency)

serb sas - glucarpidase - metabolic side effects of drugs and substances - všetky ostatné terapeutické produkty - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.